Working… Menu
Trial record 6 of 852 for:    Ketamine

Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03450499
Recruitment Status : Completed
First Posted : March 1, 2018
Last Update Posted : August 20, 2019
Information provided by (Responsible Party):
prahlad adhikari, B.P. Koirala Institute of Health Sciences

Brief Summary:
This randomized double blind study will be conducted in pregnant woman planned for non elective cesarean section under spinal anesthesia. Ketamine group will receive intravenous 0.25 mg/kg and placebo group will receive same amount of normal saline after spinal anesthesia prior to skin incision. Postoperative outcomes measures are total opioid consumption and pain scores for 24 hrs.

Condition or disease Intervention/treatment Phase
Non Elective Cesarean Section and Ketamine Analgesia Drug: Ketamine Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section
Actual Study Start Date : April 1, 2018
Actual Primary Completion Date : March 7, 2019
Actual Study Completion Date : March 7, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ketamine

Arm Intervention/treatment
Experimental: analgesic effects of ketamine
the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
Drug: Ketamine
the analgesic affects of ketamine will be compared between the experimental and placebo group.
Other Name: ketamine hydrochloride

Placebo Comparator: placebo
they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
Drug: Placebo
the analgesic requirement will be calculated in placebo group.

Primary Outcome Measures :
  1. Total opioid requirement postoperatively [ Time Frame: 24 hrs ]
    Total opioid required up to 24 postoperatively in ketamine and placebo group.

Secondary Outcome Measures :
  1. Postoperative numerator rating scores(NRS)up to 24 hrs . postoperative ) [ Time Frame: 24 hrs ]
    • Postoperative NRS Scores (on arrival to Post operative care unit), 2, 4, 6, 8, 12 and 24 h ).The NRS ranges from 0- 10 and 0 refers to no pain and 10 means extreme possible pain perceived.

  2. Time to first perception of pain [ Time Frame: 24 hrs ]
    Time to first perception of pain

  3. Incidence of side effects [ Time Frame: 24 hrs ]
    Incidence of post operative nausea and vomiting, shivering, sedation scores, side effects related to ketamine during the first 24h

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • • All women at term(>or =37 weeks of gestation)

    • Healthy
    • American Society of Anesthesiologists(ASA) class1 and 2
    • Women undergoing non-elective caesarean section whose anesthetic plan is for spinal anesthesia with bupivacaine and fentanyl

Exclusion Criteria:

  • • Women with American society of anesthesiologist physical status>2

    • Body mass index >or =40 kg per square meter
    • Height <150 cm
    • Any contraindication to the spinal anesthesia
    • History of substance abuse
    • History of hallucinations
    • Chronic opioid therapy
    • Chronic pain or on any pain medication currently
    • Patient with maternal complications,like cardiovascular disease pre-eclampsia,diabetes,multiple gestation,known fetal abnormality
    • Cases with severely compromised fetus where immediate administration of general anesthesia is required.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03450499

Layout table for location information
BP Koirala Institute of Health Sciences (BPKIHS)
Dharān Bāzār, Koshi, Nepal, 56700
Sponsors and Collaborators
B.P. Koirala Institute of Health Sciences

Layout table for additonal information
Responsible Party: prahlad adhikari, doctor, B.P. Koirala Institute of Health Sciences Identifier: NCT03450499     History of Changes
Other Study ID Numbers: IRC/1089/017
First Posted: March 1, 2018    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Perceptual Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action